Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Metabolism and Lipids for the Mount Sinai Health System, New York, New York. He received his medical degree at Tulane University, New Orleans, Louisiana, and went on to complete his residency in internal medicine at Brigham and Women’s Hospital, Boston, Massachusetts, followed by a fellowship in cardiovascular medicine at The University of Chicago, Chicago, Illinois.

Dr Rosenson is a Fellow of the American College of Cardiology (FACC),  American College of Physicians (FACP), College of Chest Physicians (FCCP), Fellow of the American Heart Association (FAHA), European Society of Cardiology (FESC) and National Lipid Association (FNLA).  He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine, and was named New York Top Doc from 2015 to 2021 and USA Top Doctor in 2019. Dr Rosenson was named recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology in 2015, 2016, 2017,  2019 and 2020. The International Academy of Cardiology honored him with the Jan J. Kellerman Memorial Award in 2016 for distinguished contributions in the field of cardiovascular disease prevention. In 2017, UpToDate recognized him for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association.

He is Section Editor on Metabolic Disorders for the Journal of the American College of Cardiology, and Section Editor on Lipid Disorders for UptoDate.


Panel Discussion: EAS/NLA joint symposium - Registry updates91th EAS Congress 2023EAS/NLA joint symposium - Registry updatesThe GOULD registry91th EAS Congress 2023EAS/NLA joint symposium - Registry updatesThe resistant patients with HoFH – novel approaches to reducing LDL cholesterolFH Week89th EAS Congress 2021(ReviewDyslipidemiaMonogenicCholesterolLipidologyHypercholesterolemiaFHhoTreatmentHDLPrimary HyperlipidemiaHypolipidemic drugsTreatment)